Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.56 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.56 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.56 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.56 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4778092 | 0.88 | CACNA2D1 (0.58) | KMT2ACACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL4776603 | 0.83 | KMT2A (0.60) | CHRM1KMT2ACACNA2D1CACNA1BCACNB1 | |
| SCHEMBL4772720 | 0.80 | CACNA1G (0.54) | CACNA2D1CACNA1BCACNB1CACNA1CMAPT | |
| SCHEMBL27723065 | 0.78 | KMT2A (0.57) | CHRM1KMT2ACACNA2D1CACNA1BCACNB1 | |
| SCHEMBL4778274 | 0.76 | DPP4 (0.61) | CHRM1KMT2ACACNA2D1CACNA1BCACNB1 | |
| SCHEMBL4775433 | 0.76 | KMT2A (0.54) | CHRM1KMT2ACACNA2D1CACNA1BCACNB1 | |
| SCHEMBL29321595 | 0.76 | KMT2A (0.71) | CHRM1KMT2ACACNA2D1CACNA1BCACNB1 | |
| SCHEMBL7391221 | 0.76 | DPP8 (0.62) | KMT2ACACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL7391223 | 0.76 | DPP8 (0.62) | KMT2ACACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL4775004 | 0.76 | AKT1 (0.55) | CHRM1KMT2ACACNA2D1CACNA1BCACNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996550-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | claimed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | claimed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | claimed |
| EP-1996550-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | disclosed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | HNMT, HDAC5, HDAC4 | CHRM1 557/4885KMT2A 41/4885CACNA2D1 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.